2024 Awards

Now in their 20th edition, the French American Business Awards recognize Excellence, Innovation, and Leadership based in New England and France.​

2024 Categories

  • Innovation Award (including DeepTech & AI)
  • Sustainability Award (including GreenTech, ClimateTech & CSR)
  • Life Sciences Award - Less than 100 employees
  • Life Sciences Award - 100+ employees
  • Woman in Business of the Year (under the umbrella of FACCNE's Women in Business committee)
  • French Tech Boston Company of the Year 

Congratulations 2024 Winners!

Innovation Award


Co-founded by Valerie Gharagouzloo and Dr. Codi Amir Gharagouzloo, Ph.DImaginostics is pioneering health technology that revolutionizes precision medicine to promote longevity and healthy aging.


Sustainability Award


Represented by Laurent Canneva, Co-founder and CEO, Spare-it innovates in waste management by unlocking data to help organizations measure and reduce in-building waste, connecting data with occupants to close the loop.


Life Sciences - Small Companies Award


Represented by Domitille Gontharet, Business Development Associate and PharmD, Owkin is an AI biotechnology company using AI to identify new treatments, de-risk and accelerate clinical trials, and develop diagnostic tools.


Life Sciences - Large Companies Award


Represented by Kévin Alessandri, Co-founder and US VP, TreeFrog Therapeutics has developed C-Stem, a proprietary 3D scalable technology platform that significantly reduces treatment costs in stem cell therapy.


Woman in Business of the Year: Adelaide Spencer

Co-founder of Acute Industry LLC, a woman-owned construction company specializing in equipment rental and flagging services. Adelaide Spencer is also the Marketing Manager at NFI Corp and founder of Custom Event Print LLC.  She is a passionate advocate for diversity, social impact, and workforce reintegration.


French Tech Boston Company of the Year: Alkeus Pharmaceuticals

Representated by Leonide Saad, Co-founder, President, and CEO,  Alkeus Pharmaceuticals, Inc. is developing therapies for serious eye diseases. Their lead asset, gildeuretinol acetate (ALK-001), is in advanced stages for treating Stargardt disease and age-related macular degeneration. Leonide Saad emphasized 14 years of perseverance and dedication to patients in his acceptance speech.

2024 Gold Sponsors

Silver Sponsors

Bronze Sponsors


Share this page Share on FacebookShare on TwitterShare on Linkedin